Showing 321 - 340 results of 27,431 for search '(( 50 ((c decrease) OR (a decrease)) ) OR ( 50 ((nn decrease) OR (mean decrease)) ))', query time: 1.06s Refine Results
  1. 321
  2. 322
  3. 323
  4. 324
  5. 325
  6. 326

    Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

    Published 2016
    “…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
  7. 327
  8. 328
  9. 329
  10. 330
  11. 331
  12. 332
  13. 333
  14. 334
  15. 335
  16. 336
  17. 337

    MAP-2 decrease follows the early PSA-NCAM reduction induced by glutamate exposure. by María Fernanda Podestá (639243)

    Published 2014
    “…(B) Quantification of total PSA-NCAM area showed decreased levels 3 h after glutamate exposure, which remained low for the rest of the studied period (3–12 h). …”
  18. 338
  19. 339

    Fenretinide decreases levels of PAX3/FOXO1 and its target genes in aRMS cell lines. by David Herrero Martín (286820)

    Published 2013
    “…D) Fenretinide did not decrease mRNA levels of FOXO1 in aRMS cells. qRT–PCR was carried out after treatment with an IC<sub>50</sub> concentration of fenretinide during different time points (24–48–72 hours). …”
  20. 340